comparemela.com

Latest Breaking News On - Myelodysplastic syndromes - Page 8 : comparemela.com

First-Line Treatment of Lower-Risk MDS with Symptomatic Anemia

Amy DeZern, MD, MHS, provides clinical insights on the first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Amy dezernEvolving treatment landscapeMyelodysplastic syndromesLine treatmentFirst line treatmentFirst line therapiesSymptomatic anemiaMds treatmentMyelodysplastic syndromes treatment

Signaling Pathways in MDS a Fruitful Area for Research, Drug Development

A review of recent research into myelodysplastic syndromes (MDS) shows a range of potential therapeutic targets.

Bristol myers squibbPi plcβ1Myelodysplastic syndromesPlcg1 expression

Risk Stratification of Myelodysplastic Syndromes

Hematologist-oncologists discuss the risk stratification of patients with myelodysplastic syndromes and how patient risk status determines prognosis.

Evolving treatment landscapeMyelodysplastic syndromesMds risk stratificationPrognostic scoring systemsEvaluating riskIpss rIpss mRisk categoriesHigher risk mdsLower risk mds

Diagnosis of Myelodysplastic Syndromes (MDS)

A panel of experts on myelodysplastic syndromes (MDS) introduce themselves and provide an overview of diagnosis practices, highlighting common symptoms and the typical patient presentation.

Evolving treatment landscapeMyelodysplastic syndromesMds presentationMds diagnosisMyelodysplastic syndromes diagnosisPatient presentationBone marrow biopsyMyelodysplastic syndromeMds patient presentation

Real-World Data Show Suboptimal Efficacy With AZA in Treatment-Naïve High-Risk MDS

Pulling data from a US electronic health record–based database, researchers found low rates of complete remission and poor overall survival among 382 patients who had myelodysplastic syndromes (MDS) receiving first-line azacytidine (AZA).

Eastern cooperative oncology groupClinical lymphomaMyelodysplastic syndromesFirst line azacytidine

vimarsana © 2020. All Rights Reserved.